Colorectal Cancer

Product Marketing Application Accepted For European Review

Published in Cancer Weekly, July 29th, 1996

Neoprobe Corp., Dublin, Ohio, announced that its marketing application for RIGScan CR49 was formally accepted for review by the European regulatory authorities.

David C. Bupp, Neoprobe, said, "They will now begin a statutory review procedure for our RIGScan CR49 product, which is designed to locate cancerous tissue during surgery for patients with metastatic cancer of the colon or rectum (colorectal)." Bupp continued, "With an average seven to eight month approval period by the European regulatory authorities, we look forward to a possible product launch for RIGScan CR49 in Europe as early as the first quarter of 1997."

The company has planned to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry